SPY313.78-3.27 -1.03%
DIA259.04-3.96 -1.51%
IXIC10,343.89-89.76 -0.86%

Tonix Pharma Now Expects Phase 3 RELIEF Study Results in Q4 2020 Rather Than Q1 2021 Due to Faster-Than-Expected Enrollment

Benzinga · -